Sanford Biotech
– translating science into innovative cell therapies

 

Sanford Biotech develops therapies based on stem cells (MSC) and growth factors (PRP), conducting translational research that combines human and veterinary medicine.

 


Sanford Biotech is a company with Polish scientific background and international experience (Germany, USA) , whose translational research forms the basis for commercial cell therapies with high licensing potential.

 

 

dr Joanna Sanford

 

Sanford Biotech and Warsaw University of Life Sciences join forces in translational medicine

 

Sanford Biotech has signed a strategic cooperation agreement with the Centre for Translational Medicine at the Warsaw University of Life Sciences (SGGW), opening a new stage in the development of stem cell therapies (ATMP) for animals and humans.

The partnership combines Sanford Biotech's advanced biological platforms with the scientific and infrastructural resources of SGGW, accelerating the path from research to registration of innovative therapies with global potential...

 

read more...

Technologies and products

 

Cats and dogs

Companion animals are found in 50% of households in Europe – 46 per cent are dogs and cats, with the remaining 4 per cent being other companion animals. In numbers, this translates to 127 million cats and 104 million dogs, making the continent one of the largest pet care markets in the world. 


Market growth is driven by a change in the perception of animals – they are increasingly treated as family members, which translates into growing expenditure by owners on prevention, diagnostics and advanced therapies, including biological and cellular therapies for dogs and cats.


Sanford Biotech is preparing professional drug lines for the companion animal market:

  • SB-REG-CORTO – innovative cell therapy for osteoarthritis in dogs
  • SB-REG-CSKIN/CORTO – cell therapy for dogs and cats with AD (atopic dermatitis)        
  • SB-REG-HMILA – ILA-1 biological therapy for horses and dogs
  • SB-REG-CDM – stem cell therapy in canine neurology

Professional market – horses and dairy cattle

 

In Europe, the horse population is estimated at 7 million, while the dairy cow population is estimated at 19.2 million. In the case of horses, there has been a clear shift in status from "farm animals" to companion animals with high breeding or sporting value. Horses are increasingly receiving care similar to that provided to humans, with the use of cell therapies, PRP and advanced imaging diagnostics, including dedicated Sanford Biotech therapies. In addition, we are developing professional drug lines for horses:

👉See how SB-REG-HORTO – stem cell therapy for horses – can influence the future of this market. 

 

In the dairy cow sector, innovations focus on diseases that directly affect herd productivity.  One of the most promising projects is SB-REG-KMAS, developed to treat mastitis (udder inflammation) – a disease that causes up to 10% of dairy cows to be culled each year. In Poland alone, the dairy cow population exceeds 1.3 million, which shows the scale of the problem and the market potential of the therapy.

 

👉That is why we are working on SB-REG-KMAS – stem cells in the treatment of mastitis in cows.